News | January 2, 2013

Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia According to data reported at Kidney Week 2012, an ongoing Phase 2b study of patiromer met the interim analysis primary endpoint of mean...

News | January 17, 2013

Pearl Therapeutics Strengthens Its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development REDWOOD CITY, CALIF., January 17, 2013 – Pearl Therapeutics Inc. today announced that Michael Riebe, Ph.D. has joined Pearl...

News | January 29, 2013

Oxford Immunotec and Lophius Biosciences sign licensing and collaboration agreements Oxford, UK; January 29th, 2013 – Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease and Lophius Biosciences, a...

News | February 20, 2013

Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia Redwood City, CA, February 20, 2013 – Relypsa, Inc., a clinical-stage biopharmaceutical company, announced that he first patient has been enrolled in the company’s pivotal...

News | February 25, 2013

NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients Elegant Solution Enhances Company’s Recent Nocturnal Clearance in Europe LAWRENCE, Mass., Feb. 25, 2013 /PRNewswire/ — NxStage® Medical, Inc. (Nasdaq: NXTM),...

News | February 25, 2013

Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI DISCOVER 2 Study Meets Primary & Secondary Endpoints Conference Call and Webcast Today at 8:30 A.M. EST to Discuss Results CHICAGO, Feb....
tristique id, dapibus ipsum leo. eleifend accumsan